EUMETSAT
14.12.2022 10:45:38 CET | Business Wire | Press release
Tonight’s launch of a highly advanced meteorological satellite from, Kourou, French Guiana, heralds the start of a new era for weather forecasting in Europe, EUMETSAT Director-General Phil Evans said.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005463/en/
MTG-I1 is successfully launched on an Ariane-5 rocket from Kourou, French Guiana (Photo: EUMETSAT)
The satellite, MTG-I1, is the first of a new generation of meteorological satellites carrying more advanced and precise instruments for monitoring and forecasting severe weather events such as storms, lightning, fog and wildfires.
It was successfully launched on an Ariane-5 rocket at 21:30 CET and is on its way to its correct orbit, 36,000km above the Equator.
“MTG-I1 will generate images of Europe and Africa every 10 minutes, faster than has been possible up until now, and in higher resolution, more precise detail,” Evans said.
“This data will help meteorologists meet one of their main challenges – timely and accurate forecasts of rapidly developing severe weather events – so that citizens, first responders and civil authorities can take appropriate action.
“The satellite’s lightning imager will continuously map lightning flashes between clouds and from clouds to the ground, which is a first for Europe with significant community and aviation industry safety benefits.”
MTG-I1 – full name Meteosat Third Generation – Imager 1 – will undergo a 12-month commissioning phase, in which its instruments will be calibrated and the data they produce validated, before becoming operational.
It will be operated from EUMETSAT’s headquarters in Darmstadt, Germany.
“Meteosat Third Generation is a European success story,” Evans said. “No European nation could afford to develop and operate such a system on its own. By combining the resources of our 30 member states, including their scientific and technical expertise, we are able to bring about a new era in weather and climate monitoring.”
More information about MTG-I1 can be found here.
Brochure containing facts and figures and other information about the MTG system can be found here.
The full Meteosat Third Generation constellation will comprise two imaging satellites and, for the first time, a sounding satellite. MTG – Sounder 1, is expected to be launched in 2024.
MTG-I1 was built by Thales Alenia Space under contract by the European Space Agency (ESA). ESA is responsible for procuring the satellites from industry fulfilling EUMETSAT’s requirements.
Thales Alenia Space Cannes is the prime industrial partner for the development of the MTG-I satellites. TAS works in close cooperation with:
• OHB-Bremen, which assembled, integrated and tested the platform
• LEONARDO in Italy, which provided the Lightning Imager instrument
• Thales Alenia Space Italy, which delivered the Data Collection and GEO SAR instruments
• Thales Alenia Space Cannes also integrated the Flexible Combined Imager.
For more information, visit the EUMETSAT website.
About EUMETSAT
EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.
Three Meteosat Second Generation satellites in geostationary orbit deliver continuous observations of fast developing severe weather events over Europe, Africa and the Indian Ocean. The first of the Meteosat Third Generation satellites was launched in December 2022 and will undergo 12 months’ in-orbit commissioning. Two polar-orbiting Metop satellites provide data of pivotal importance for forecasts up to 10 days ahead. The first of the second-generation Metop satellites is expected to be launched in 2025.
EUMETSAT’s archive of satellite observations over more than 40 years provides climate scientists around the world with long-term, homogenous data necessary for monitoring climate change.
EUMETSAT is a key partner in the European Union’s Copernicus Earth observation programme. It operates the Copernicus Sentinel-3 and -6 ocean-monitoring missions, and will operate the upcoming CO2M mission, to monitor carbon dioxide emissions. EUMETSAT will fly the Copernicus Sentinel-4 and -5 missions on board its own MTG and Metop-SG satellites. Data from these Sentinels, and EUMETSAT’s own missions, are provided to the Copernicus climate, atmosphere monitoring and marine environment services. Along with European Space Agency and the European Centre for Medium-Range Weather Forecasts, EUMETSAT is a partner in the EU’s DestinE initiative, creating digital twins of the entire Earth system.
Together with NASA, NOAA, the EU, ESA and with support from the French Space Agency, CNES, EUMETSAT is a partner in the Jason and Copernicus Sentinel-6 ocean-monitoring missions.
EUMETSAT cooperates with agencies around the world, securing additional satellite data of benefit to weather forecasting and climate monitoring.
EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005463/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
